🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Lawrence E. Flaherty

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma”.

Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

Cancer(2024)10.1002/cncr.35587

N/A

0.539DataRank · unranked

9 citations

James Moon, T. Vincent, John P. Fruehauf, Lawrence E. Flaherty, Martin J. Bury +8 more

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.5_suppl.60

N/A

0DataRank · unranked

1 citations

Sandra J. Lee, Ni Kang, F. Stephen Hodi, Uma N. M. Rao, Gary I. Cohen +5 more

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002535

N/A

0DataRank · unranked

31 citations

Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, Omid Hamid +16 more